protein 5 fabp5  (Proteintech)

Journal: Molecular Medicine Reports

Article Title: Stigmasterol exerts antiglioma effects by regulating lipid metabolism

doi: 10.3892/mmr.2024.13351

Figure Lengend Snippet: Primers used for reverse transcription quantitative PCR.

Article Snippet: The following primary antibodies were utilized for western blotting: Rabbit anti-fatty acid binding protein 5 (FABP5) antibody (1:2,000; cat. no. 12348-1-AP; Proteintech Group, Inc.), rabbit anti-α-1B adrenergic receptor (ADRA1B) antibody (1:1,000; cat. no. 22419-1-AP; Proteintech Group, Inc.) and mouse anti-β-actin antibody (1:5,000; cat. no. T0022; Affinity Biosciences).

Techniques: Reverse Transcription, Sequencing

Journal: Molecular Medicine Reports

Article Title: Stigmasterol exerts antiglioma effects by regulating lipid metabolism

doi: 10.3892/mmr.2024.13351

Figure Lengend Snippet: Construction and validation of a prognostic model associated with stigmasterol target genes. (A) Venn diagram of potential targets of stigmasterol in the treatment of GBM, prognosis-related genes of patients with GBM and lipid metabolism-related genes. (B) Two prognosis-related target mRNAs of stigmasterol for GBM treatment were selected. (C and D) Least absolute shrinkage and selection operator variable screening process. (E) Distribution of survival status and risk score of patients with GBM in the training set. (F) Expression characteristics of the two prognosis-related target mRNAs of stigmasterol for GBM treatment in the training set. (G) ROC curve for patient survival of the training set. (H) Survival analysis between the two risk subgroups in the training set. (I) ROC curve for patient survival of the internal validation set. (J) Survival analysis between the two risk subgroups in the internal validation set. (K) ROC curve for patient survival of the external validation set. (L) Survival analysis between the two risk subgroups in the external validation set. GBM, glioblastoma; ROC, receiver operating characteristic; FABP5, fatty acid binding protein 5; ADRA1B, α-1B adrenergic receptor; AUC, area under the curve.

Article Snippet: The following primary antibodies were utilized for western blotting: Rabbit anti-fatty acid binding protein 5 (FABP5) antibody (1:2,000; cat. no. 12348-1-AP; Proteintech Group, Inc.), rabbit anti-α-1B adrenergic receptor (ADRA1B) antibody (1:1,000; cat. no. 22419-1-AP; Proteintech Group, Inc.) and mouse anti-β-actin antibody (1:5,000; cat. no. T0022; Affinity Biosciences).

Techniques: Selection, Expressing, Binding Assay

Journal: Molecular Medicine Reports

Article Title: Stigmasterol exerts antiglioma effects by regulating lipid metabolism

doi: 10.3892/mmr.2024.13351

Figure Lengend Snippet: Effects of stigmasterol on lipid metabolism and the expression of related target genes in GBM cells. (A) Effect of stigmasterol on free fatty acid levels in GBM cells. (B) Effect of stigmasterol on total cholesterol levels in GBM cells. (C) Effect of stigmasterol on the mRNA expression of the two target genes (FABP5 and ADRA1B) in GBM cells. (D) Effect of stigmasterol on the expression of the proteins encoded by the two target genes in GBM cells. (E) Molecular docking of the protein encoded by FABP5 with stigmasterol. (F) Molecular docking of the protein encoded by ADRA1B with stigmasterol. *P<0.05 and **P<0.01. GBM, glioblastoma; FABP5, fatty acid binding protein 5; ADRA1B, α-1B adrenergic receptor.

Article Snippet: The following primary antibodies were utilized for western blotting: Rabbit anti-fatty acid binding protein 5 (FABP5) antibody (1:2,000; cat. no. 12348-1-AP; Proteintech Group, Inc.), rabbit anti-α-1B adrenergic receptor (ADRA1B) antibody (1:1,000; cat. no. 22419-1-AP; Proteintech Group, Inc.) and mouse anti-β-actin antibody (1:5,000; cat. no. T0022; Affinity Biosciences).

Techniques: Expressing, Binding Assay

Journal: Biomolecules

Article Title: Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies

doi: 10.3390/biom14070833

Figure Lengend Snippet: Dynamic range of microglial subtypes in different conditions. Microglia exhibit various reactive states, representing a significant departure from the previously used classical (neurotoxic) and alternative (neuroprotective) activation classifications. This image illustrates the multifunctional roles of microglia within the dynamic immune landscape. Abbreviations: IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; IL-18, interleukin-18; IL-4, interleukin-4; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor-β; NO, nitric oxide; IL-4, interleukin-4; ROS: reactive oxygen species; INF-γ, Interferon-γ; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; DAM, disease associate microglia; MGnD, Microglial neurodegenerative-phenotype; LDAM, lipid-accumulating microglia; WAM, white matter-associate microglia; TMEM119, transmembrane protein 119; P2RY12, P2Y purinoceptor12; CX3CR1, CX3C chemokine receptor 1; TREM2, triggering receptor expressed on myeloid cells 2; CST7, cystatin 7; RAP1B, RAS related protein 1b; RAK1, receptor for activated C kinase1; CD63, cluster of differentiation 63; Clec7a, C-type lectin domain containing 7A; SNX17, sorting nexin 17; Lgals3, Galectin-3; Gpnmb, Glycoprotein-NMB; Fabp5, fatty acid-binding protein 5; ccl2, chemokine (C-C motif) ligand 2; TLR2/4, Toll-like receptor 2/4; CD47, cluster of differentiation 47; CSF1R, colony-stimulating factor 1 receptor; AD, Alzheimer’s disease; PD, Parkinson’s disease; ALS, amyotrophic lateral sclerosis.

Article Snippet: The MGnD is characterized by specific markers, including the C-type lectin domain family 7 (Clec7a), Galectin-3 (Lgals3), Glycoprotein-NMB (Gpnmb), integrin alpha X (Itgax), app1, fatty acid-binding protein 5 (Fabp5), and Ccl2.

Techniques: Activation Assay, Derivative Assay, Binding Assay

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: The Up-Regulated and Down-Regulated Top 5 Proteins Between the Two Groups

Article Snippet: Mannose receptor C-type 1 (MRC1) kits (Cat: CSB-E09961h), cadherin 13 (CDH13) kits (Cat: CSB-E13817h), cluster of differentiation 5 antigen-like (CD5L) kits (Cat: CSB-E13423h), matrix metalloproteinase-2 (MMP2) kits (Cat: CSB-E04675h), plasma protease C1 inhibitor (SERPING1) kits (Cat: CSB-EL021086HU), insulin-like growth factor-binding protein 5 (IGFBP5) kits (Cat: CSB-EL010901HU), tripartite motif-containing protein 28 (TRIM28) kits (Cat: CSB-EL024502HU), and fatty acid-binding protein 5 (FABP5) kits (Cat: CSB-EL007946HU) were purchased from Cusabio (Wuhan, China).

Techniques:

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: Validation of the top 5 up and down-regulated proteins in an independent validation cohort. ( A – E ) comparison of serum MRC1, CDH13, LTA4H, CD5L and MMP2 concentrations between the eCRSwNP and neCRSwNP groups. ( F – J ) comparison of serum SERPING1, IGFBP5, TRIM28, CHL1 and FABP5 levels between the eCRSwNP and neCRSwNP groups. *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Mannose receptor C-type 1 (MRC1) kits (Cat: CSB-E09961h), cadherin 13 (CDH13) kits (Cat: CSB-E13817h), cluster of differentiation 5 antigen-like (CD5L) kits (Cat: CSB-E13423h), matrix metalloproteinase-2 (MMP2) kits (Cat: CSB-E04675h), plasma protease C1 inhibitor (SERPING1) kits (Cat: CSB-EL021086HU), insulin-like growth factor-binding protein 5 (IGFBP5) kits (Cat: CSB-EL010901HU), tripartite motif-containing protein 28 (TRIM28) kits (Cat: CSB-EL024502HU), and fatty acid-binding protein 5 (FABP5) kits (Cat: CSB-EL007946HU) were purchased from Cusabio (Wuhan, China).

Techniques: Comparison